Industry news that matters to you.  Learn more

Clarient Joins the HistoRX Clinical Trials Network

Clarient, a GE Healthcare company, and HistoRx, Inc., have signed a definitive agreement to provide pharma services using AQUA technology to their growing lists of pharma clients. By implementing HistoRx’s AQUA technology in Clarient’s CLIA laboratory, the two companies will apply their complementary capabilities to serve pharma companies’ growing need for biomarker analysis in clinical trials. Use of tissue biomarkers to characterize a patient’s tumor is becoming a crucial element of personalized cancer care. AQUA technology is an automated, quantitative IHC testing method that enables standardized precision measurement of protein biomarkers in tissue as an aid to a pathologist’s diagnosis.

ResearchDx and CompanDX Announce Strategic Partnership

ResearchDx, LLC of Irvine, California yesterday announced a strategic partnership with CompanDX of Nottingham UK. ResearchDx and CompanDX have forged a unique partnership to offer a full capability to discover and deliver novel molecular diagnostic tests for clients in the healthcare setting. CompanDX uses its unique “Distiller” platform to deliver small composite biomarker signatures from complex data of high dimensionality, which are commonplace in clinical development of therapeutics. ResearchDx draws on its broad capability to design, produce and validate tests ready for the market and represents a new breed of service provider, the first CDO to offer turnkey solutions for companion diagnostic delivery.

OSI Pays Aveo $25M for Rights to Use Human Response Platform

The Astellas subsidiary OSI Pharmaceuticals will pay Aveo Pharmaceuticals $25 million to exercise its option to take on specific elements of the latter’s Human Response platform (HRP) technology in support of its own clinical development programs. The transferred technology will include components of the HRP platform for identifying and characterizing novel epithelial-mesenchymal transition (EMT) agents and patient-selection biomarkers.

Ingenuity Systems and Sage Bionetworks Collaborate to Enable Predictive Disease Network Research

Ingenuity Systems, a leading provider of information solutions for life science researchers, today announced a new collaboration with Sage Bionetworks, a non-profit leader in predictive disease network research. Under the collaboration, Sage will leverage IPA, Ingenuity’s industry-leading analysis software, and the Ingenuity Knowledge Base of structured biomedical Findings, to inform and enhance Sage’s predictive disease networks. Additionally, Sage’s web portal will provide links to the Ingenuity Knowledge Base and to IPA, to help visitors access timely, context-rich biomedical information and better understand it in a biological context. Sage’s content, algorithms, and predictive disease networks will also be made available within Ingenuity products like IPA.